Kinex Licenses China Rights for Cancer Molecule to Hanmi Pharma

Kinex Pharmaceuticals, a privately held pharma in New York State, has out-licensed China rights for its lead molecule, KX01, to Hanmi Pharmaceutical Co. of South Korea. KX01 has completed a Phase I trial for end-stage cancer in the US, where it showed a clinical response in 25% of the patients. Hanmi has rights to KX01 in China and other selected Asian countries for all oncology indications. Financial terms were not disclosed. More details.... Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});